NCT00317252View on ClinicalTrials.gov

Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Kidney Failure
Interventions
DRUG

Hold ACEI or ARB

Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)

Trial Locations (1)

L8L 2X2

Hamilton General Hospital, Hamilton

All Listed Sponsors
lead

Hamilton Health Sciences Corporation

OTHER

NCT00317252 - Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization | Biotech Hunter | Biotech Hunter